Regencell Bioscience(US:RGC) Prnewswire·2025-11-20 15:00Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Regencell Bioscience Holdings Limited and its officers or directors [1][2]. Group 1: Investigation Details - Regencell disclosed on October 31, 2025, that it received a subpoena from the U.S. Department of Justice (DOJ) regarding an investigation into trading of its Ordinary Shares [2]. - The DOJ has requested documents and communications related to corporate operational, financial, and accounting matters [2]. - Regencell anticipates incurring significant legal costs and may face fines or penalties exceeding its insurance coverage due to the investigation [2]. Group 2: Market Reaction - Following the announcement of the DOJ investigation, Regencell's stock price dropped by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025 [2].